HK1122470A1 - Methods and products for treatment of diseases - Google Patents
Methods and products for treatment of diseasesInfo
- Publication number
- HK1122470A1 HK1122470A1 HK09103146.8A HK09103146A HK1122470A1 HK 1122470 A1 HK1122470 A1 HK 1122470A1 HK 09103146 A HK09103146 A HK 09103146A HK 1122470 A1 HK1122470 A1 HK 1122470A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- diseases
- products
- treatment
- methods
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69872305P | 2005-07-12 | 2005-07-12 | |
US71115805P | 2005-08-24 | 2005-08-24 | |
US71115705P | 2005-08-24 | 2005-08-24 | |
PCT/US2006/027480 WO2007009087A2 (en) | 2005-07-12 | 2006-07-12 | Methods and products for treatment of diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1122470A1 true HK1122470A1 (en) | 2009-05-22 |
Family
ID=37637992
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09103146.8A HK1122470A1 (en) | 2005-07-12 | 2009-04-02 | Methods and products for treatment of diseases |
HK12112936.8A HK1171972A1 (zh) | 2005-07-12 | 2012-12-13 | 治療疾病的方法和產品 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12112936.8A HK1171972A1 (zh) | 2005-07-12 | 2012-12-13 | 治療疾病的方法和產品 |
Country Status (12)
Country | Link |
---|---|
US (3) | US8722651B2 (xx) |
EP (6) | EP2468318A1 (xx) |
JP (2) | JP5544458B2 (xx) |
CN (2) | CN103169714A (xx) |
DE (1) | DE202006021081U1 (xx) |
DK (1) | DK1919290T3 (xx) |
ES (1) | ES2447025T3 (xx) |
HK (2) | HK1122470A1 (xx) |
PL (1) | PL1919290T3 (xx) |
PT (1) | PT1919290E (xx) |
SI (1) | SI1919290T1 (xx) |
WO (1) | WO2007009087A2 (xx) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8980930B2 (en) | 2004-06-25 | 2015-03-17 | The Johns Hopkins University | Angiogenesis inhibitors |
EP2468318A1 (en) | 2005-07-12 | 2012-06-27 | DMI Biosciences, Inc. | Methods and products for treatment of diseases |
FR2931678B1 (fr) * | 2008-05-27 | 2010-10-01 | Cll Pharma | Utilisation du trilistane pour le traitement de la depression |
EP2445350A4 (en) | 2009-06-22 | 2012-12-26 | Dmi Acquisition Corp | METHOD AND PRODUCTS FOR THE TREATMENT OF DISEASES |
DK2326332T3 (da) * | 2009-06-22 | 2013-03-04 | Dmi Acquistion Corp | Fremgangsmåde til behandling af sygdomme |
EP2724721A1 (en) * | 2012-10-26 | 2014-04-30 | Matentzoglu, Konstantin | Composition for use in the treatment of Angelman syndrome and/or autism spectrum disorder, the use of such composition and a method for manufacturing a medicament for the treatment of Angelman syndrome and/or autism spectrum disorder |
WO2014100352A1 (en) | 2012-12-19 | 2014-06-26 | Ampio Pharmaceuticals, Inc. | Method for treatment of diseases |
CN107868117B (zh) * | 2016-09-28 | 2021-04-23 | 中国科学院苏州纳米技术与纳米仿生研究所 | 司坦唑醇糖精盐及其制备方法和应用 |
US11524079B2 (en) * | 2019-06-03 | 2022-12-13 | Aihol Corporation | Hyaluronan conjugates and uses thereof |
WO2021178448A1 (en) * | 2020-03-02 | 2021-09-10 | Motor Life Sciences, Llc | Compositions and methods for diagnosing, preventing, and treating amyotrophic lateral sclerosis in patients with hypofunctional anti-trypsin activity |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
US3296255A (en) | 1963-11-29 | 1967-01-03 | Sterling Drug Inc | 2-cyano steroids |
GB1123770A (en) | 1966-11-15 | 1968-08-14 | Sterling Drug Inc | 2-cyano-3-oxo-steroids |
US3296295A (en) | 1964-05-22 | 1967-01-03 | Squibb & Sons Inc | Norsteroids |
US4160027A (en) * | 1977-12-20 | 1979-07-03 | Sterling Drug Inc. | Steroid cyanoketones and intermediates |
FR2502098A1 (fr) | 1981-03-23 | 1982-09-24 | Huret & Fils | Dispositif perfectionne de fixation d'un derailleur sur une patte de cadre |
ES8504486A1 (es) | 1982-11-02 | 1985-05-01 | Sterwin Ag | Procedimiento de trituracion de compuestos esteroides |
US4994443A (en) * | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5714481A (en) * | 1983-08-02 | 1998-02-03 | Research Corporation Technologies, Inc. | Derivatives of 5-androsten-17 ones and 5-androstan-17-ones |
US4617299A (en) * | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
US4837212A (en) * | 1984-11-15 | 1989-06-06 | University Of Miami | Treatment of hemolytic anemia with danazol |
US4975537A (en) * | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
EP0244178A3 (en) | 1986-04-28 | 1989-02-08 | Iolab, Inc | Intraocular dosage compositions and method of use |
DE3738620A1 (de) | 1987-11-13 | 1989-05-24 | Luderschmidt Christoph | Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie |
US5407926A (en) | 1987-12-29 | 1995-04-18 | Alcon Laboratories, Inc. | Ophthalmic composition |
JP2680614B2 (ja) | 1988-08-01 | 1997-11-19 | 日清製粉株式会社 | ダナゾール組成物 |
US5990099A (en) * | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
US5372996A (en) * | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
CA2063378A1 (en) * | 1989-07-07 | 1991-01-08 | Fernand Labrie | Androgen derivatives for use in the inhibition of sex steroid activity |
DK0533703T3 (da) | 1990-06-11 | 2000-08-14 | Alcon Lab Inc | Anvendelse af steroider til hæmning af angiogenese |
US5972922A (en) * | 1990-06-11 | 1999-10-26 | Alcon Laboratories, Inc. | Steroids which inhibit angiogenesis |
JPH04149132A (ja) | 1990-10-13 | 1992-05-22 | Bairon Boeki Kk | ダナゾール水溶液 |
JPH0735335B2 (ja) | 1991-02-28 | 1995-04-19 | 五十嵐 正雄 | 子宮内膜症の治療薬 |
DK0593520T3 (da) * | 1991-06-18 | 2000-04-03 | Theramex | Forbindelser med indhold af steroider og deres anvendelse til behandling af glaucom |
WO1993010141A2 (en) | 1991-11-22 | 1993-05-27 | Alcon Laboratories, Inc. | Angiostatic steroids |
US5679666A (en) * | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
US5770592A (en) * | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
GB9200210D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
AU674681B2 (en) * | 1992-04-21 | 1997-01-09 | Schepens Eye Research Institute, Inc., The | Ocular androgen therapy in Sjogren's syndrome |
US5240929A (en) * | 1992-08-03 | 1993-08-31 | Warner-Lambert Company | 2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents |
WO1995003807A1 (en) * | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
US5646136A (en) | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
WO1995026734A1 (en) | 1994-04-04 | 1995-10-12 | Freeman William R | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
US5885591A (en) * | 1996-07-02 | 1999-03-23 | Johnson & Johnson Consumer Products, Inc. | Personal lubricant compositions |
US5929111A (en) * | 1996-12-18 | 1999-07-27 | Alcon Laboratories, Inc. | A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure |
US5993856A (en) * | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
WO1998043647A1 (en) * | 1997-03-28 | 1998-10-08 | Massachusetts Institute Of Technology, Inc. | Regulation of amyloid precursor protein (app) expression by estrogenic compounds |
US6011023A (en) * | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
US6172088B1 (en) * | 1997-11-24 | 2001-01-09 | University Of Florida Research Foundation, Inc. | Testosterone compounds and use for the protection of neurons |
US6054446A (en) * | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
EP0939124A3 (en) | 1998-02-24 | 2001-03-21 | Smithkline Beecham Plc | MGBP1 sequences |
GB9807809D0 (en) | 1998-04-09 | 1998-06-10 | Multimed Ltd | Compositions comprising ethisterone or its derivatives |
US6645954B2 (en) * | 1998-04-09 | 2003-11-11 | Multimed Limited | Compositions comprising ethisterone or its derivatives |
CA2336703A1 (en) | 1998-07-10 | 2000-01-20 | The University Of Sydney | Prophylactic treatments of neovascularisation in macular degeneration |
US20040063719A1 (en) * | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
EP1022027A1 (en) * | 1999-01-22 | 2000-07-26 | Applied Research Systems ARS Holding N.V. | Tumor necrosis factor antagonists and their use in endometriosis |
ATE225405T1 (de) * | 1999-07-09 | 2002-10-15 | Pasteur Institut | Verfahren zur diagnose oder zur prognose von alzheimer krankheit: therapeutische zusammensetzung zur verhinderung oder zur behandlung von alzheimer krankheit |
US6610674B1 (en) * | 1999-09-28 | 2003-08-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone analogs |
JP4837861B2 (ja) * | 1999-10-21 | 2011-12-14 | アルコン,インコーポレイティド | ドラッグデリバリ製剤 |
WO2001030337A2 (en) | 1999-10-22 | 2001-05-03 | Orbon Corporation | Ophthalmic formulation of dopamine antagonists |
US6562369B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers |
GB2345851B (en) | 2000-01-18 | 2004-05-26 | Gavin Paul Vinson | A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour |
US20020055512A1 (en) * | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
KR20010113918A (ko) | 2000-03-10 | 2001-12-28 | 추후제출 | 후안부 안과 질환을 치료하고 예방하기 위한 방법 및 조성물 |
CA2417960C (en) | 2000-08-04 | 2012-07-10 | Dmi Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
US20040082557A1 (en) * | 2001-01-26 | 2004-04-29 | Wajszczuk Charles Paul | Methods for treating estrogen-dependent disorders |
WO2002069977A1 (en) | 2001-03-01 | 2002-09-12 | Hollis-Eden Pharmaceuticals, Inc. | Use of certain steroids for treatment of blood cell deficiencies |
GB2375958B (en) * | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
US6936599B2 (en) * | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
US20030003144A1 (en) * | 2001-05-01 | 2003-01-02 | Keller Brian C. | Sustained release formulations for nifedipine, dextromethorphan, and danazol |
FR2825277B1 (fr) * | 2001-05-30 | 2004-10-15 | Oreal | Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd |
US20030232798A1 (en) * | 2001-06-12 | 2003-12-18 | Yadon Arad | Adrenal enzyme inhibitors |
US20030050291A1 (en) * | 2001-06-12 | 2003-03-13 | Yadon Arad | Adrenal enzyme inhibitors |
WO2003013609A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
EP1494699A4 (en) | 2002-04-11 | 2009-07-22 | Childrens Medical Center | METHOD FOR INHIBITING VASCULAR HYPERPERMEABILITY |
JP2006506445A (ja) * | 2002-08-28 | 2006-02-23 | ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド | 治療処置の方法 |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
EP1572178B1 (en) * | 2002-12-18 | 2006-05-03 | Laboratoires Besins International | Treatment of mastalgia with 4-hydroxy tamoxifen |
NZ540885A (en) * | 2002-12-20 | 2009-02-28 | Chakshu Res Inc | Ophthalmic formulation for the prevention and treatment of ocular conditions |
JP2006515026A (ja) * | 2003-01-02 | 2006-05-18 | フェムファーマ ホールディング カンパニー, インコーポレイテッド | 乳房の疾患および障害の処置のための薬学的調製物 |
GB2400554B (en) | 2003-04-16 | 2007-04-18 | George Margetts | Treatment of angiotensin II-induced cardiovascular disease |
WO2004103406A1 (ja) * | 2003-05-26 | 2004-12-02 | Japan Science And Technology Agency | 血小板の減少または増加を伴う疾患の治療用組成物 |
GB0313612D0 (en) * | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
EP1691795A2 (en) * | 2003-12-03 | 2006-08-23 | LifeCycle Pharma A/S | Pharmaceutical compositions comprising danazol |
GB0329667D0 (en) * | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
US20050143362A1 (en) * | 2003-12-31 | 2005-06-30 | Mclane Michael W. | Danazol for treatment of hypogonadism in the adult male |
US7442681B2 (en) * | 2004-02-10 | 2008-10-28 | University Of Virginia Patent Foundation | Method of inhibiting vascular permeability |
CA2557724A1 (en) | 2004-02-27 | 2005-10-06 | Centocor, Inc. | Methods and compositions for treating il-13 related pathologies |
WO2005097121A1 (en) | 2004-04-06 | 2005-10-20 | Angiogenetics Sweden Ab | Angiogenesis-affecting compounds and methods of use thereof |
US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US8980930B2 (en) * | 2004-06-25 | 2015-03-17 | The Johns Hopkins University | Angiogenesis inhibitors |
GB2420281A (en) * | 2004-11-22 | 2006-05-24 | Stegram Pharmaceuticals Ltd | Topical formulations for use in the treatment or prevention of dermatological conditions |
GB2421183A (en) * | 2004-12-17 | 2006-06-21 | Stegram Pharmaceuticals Ltd | Topical formulations for use in the treatment or prevention of skin cancers |
US20080233053A1 (en) * | 2005-02-07 | 2008-09-25 | Pharmalight Inc. | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients |
WO2006091459A2 (en) | 2005-02-24 | 2006-08-31 | Joslin Diabetes Center, Inc. | Compositions and methods for treating vascular permeability |
AU2006218654A1 (en) | 2005-03-02 | 2006-09-08 | Nascent Pharmaceutical. Inc. | Combination therapy for topical application |
EP2468318A1 (en) | 2005-07-12 | 2012-06-27 | DMI Biosciences, Inc. | Methods and products for treatment of diseases |
US7598181B2 (en) * | 2005-07-19 | 2009-10-06 | Micron Technology, Inc. | Process for enhancing solubility and reaction rates in supercritical fluids |
US8404643B2 (en) * | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
US8071779B2 (en) * | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
EP2300011A4 (en) * | 2008-05-27 | 2012-06-20 | Dmi Life Sciences Inc | METHODS AND THERAPEUTIC COMPOUNDS |
DK2326332T3 (da) * | 2009-06-22 | 2013-03-04 | Dmi Acquistion Corp | Fremgangsmåde til behandling af sygdomme |
EP2445350A4 (en) * | 2009-06-22 | 2012-12-26 | Dmi Acquisition Corp | METHOD AND PRODUCTS FOR THE TREATMENT OF DISEASES |
-
2006
- 2006-07-12 EP EP11010271A patent/EP2468318A1/en not_active Withdrawn
- 2006-07-12 EP EP11010273A patent/EP2468282A3/en not_active Withdrawn
- 2006-07-12 PT PT67873935T patent/PT1919290E/pt unknown
- 2006-07-12 CN CN2013100470002A patent/CN103169714A/zh active Pending
- 2006-07-12 EP EP11010270.4A patent/EP2462959B1/en not_active Not-in-force
- 2006-07-12 EP EP11010269A patent/EP2446887A3/en not_active Withdrawn
- 2006-07-12 DK DK06787393.5T patent/DK1919290T3/da active
- 2006-07-12 PL PL06787393T patent/PL1919290T3/pl unknown
- 2006-07-12 CN CN2006800333785A patent/CN101282646B/zh not_active Expired - Fee Related
- 2006-07-12 EP EP06787393.5A patent/EP1919290B1/en not_active Not-in-force
- 2006-07-12 DE DE202006021081U patent/DE202006021081U1/de not_active Expired - Lifetime
- 2006-07-12 ES ES06787393.5T patent/ES2447025T3/es active Active
- 2006-07-12 EP EP11010272A patent/EP2446888A3/en not_active Withdrawn
- 2006-07-12 WO PCT/US2006/027480 patent/WO2007009087A2/en active Application Filing
- 2006-07-12 SI SI200631762T patent/SI1919290T1/sl unknown
- 2006-07-12 US US11/457,063 patent/US8722651B2/en not_active Expired - Fee Related
- 2006-07-12 JP JP2008521661A patent/JP5544458B2/ja not_active Expired - Fee Related
-
2009
- 2009-04-02 HK HK09103146.8A patent/HK1122470A1/xx not_active IP Right Cessation
-
2011
- 2011-03-25 US US13/072,568 patent/US8586568B2/en not_active Expired - Fee Related
- 2011-03-25 US US13/072,545 patent/US20110171306A1/en not_active Abandoned
-
2012
- 2012-12-13 HK HK12112936.8A patent/HK1171972A1/zh not_active IP Right Cessation
-
2013
- 2013-07-16 JP JP2013147783A patent/JP5779618B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2468318A1 (en) | 2012-06-27 |
EP2462959B1 (en) | 2016-06-22 |
HK1171972A1 (zh) | 2013-04-12 |
DE202006021081U1 (de) | 2012-05-08 |
SI1919290T1 (sl) | 2014-05-30 |
DK1919290T3 (da) | 2014-04-22 |
US20070111972A1 (en) | 2007-05-17 |
EP1919290A4 (en) | 2009-10-28 |
US8586568B2 (en) | 2013-11-19 |
JP2013213059A (ja) | 2013-10-17 |
ES2447025T3 (es) | 2014-03-11 |
JP2009505950A (ja) | 2009-02-12 |
PL1919290T3 (pl) | 2014-06-30 |
JP5779618B2 (ja) | 2015-09-16 |
JP5544458B2 (ja) | 2014-07-09 |
US20110171306A1 (en) | 2011-07-14 |
EP1919290A2 (en) | 2008-05-14 |
EP2446887A2 (en) | 2012-05-02 |
EP2446887A3 (en) | 2012-08-15 |
EP2462959A1 (en) | 2012-06-13 |
EP1919290B1 (en) | 2014-01-22 |
EP2468282A2 (en) | 2012-06-27 |
EP2468282A3 (en) | 2012-09-12 |
CN103169714A (zh) | 2013-06-26 |
US8722651B2 (en) | 2014-05-13 |
PT1919290E (pt) | 2014-03-20 |
US20110171307A1 (en) | 2011-07-14 |
WO2007009087A3 (en) | 2007-07-12 |
CN101282646A (zh) | 2008-10-08 |
EP2446888A3 (en) | 2012-08-15 |
CN101282646B (zh) | 2013-03-27 |
EP2446888A2 (en) | 2012-05-02 |
WO2007009087A2 (en) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20150175T1 (xx) | Sredstva za i postupci lijeäśenja tumorskih bolesti | |
HK1171972A1 (zh) | 治療疾病的方法和產品 | |
EP1968607A4 (en) | TREATMENT OF CANCER AND OTHER DISEASES | |
IL193473A0 (en) | Amide derivatives and their application for the treatment of g protein related diseases | |
EP1933880A4 (en) | OLIGORIBONUCLEOTIDES AND METHODS OF USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | |
IL189528A0 (en) | Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases | |
EP1737482A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
IL185256A0 (en) | Method and composition for treating peripheral vascular diseases | |
EP1893043A4 (en) | TOBACCO PRODUCTS WITH REDUCED RISKS AND PROCESS FOR PRODUCING THE SAME | |
IL182643A0 (en) | Novel composition and methods for the treatment of immune related diseases | |
EP1962869A4 (en) | TREATMENT OF RESPIRATORY DISEASES | |
EP2217238A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA | |
EP1858524A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND RELATED DISEASES | |
GB2445651B (en) | Well treatment products and methods of using them | |
EP2007790A4 (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | |
PL1812797T3 (pl) | Kompozycje i sposoby do leczenia chorób hiperproliferacyjnych i zapobiegania tym chorobom | |
ZA200806095B (en) | Means and methods for the treatment of tumorous diseases | |
IL201376A0 (en) | Products for prophylaxis and /or treatment of viral diseases and method of making and using same | |
GB0620695D0 (en) | Composition and methods for the treatment of nurdegenerative disease | |
EP1924286A4 (en) | PROPHYLACTIC AND / OR THERAPEUTIC METHOD FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
GB2442881B (en) | Methods for altering gene expression and methods of treatment utilizing same | |
IL188010A0 (en) | Procedure for the treatment of purines and products thereof | |
GB0422634D0 (en) | Method of treating skin diseases | |
EP1846013A4 (en) | TREATMENT OF SKIN DISEASES | |
IL191887A0 (en) | Method for the diagnosis and treatment of cardiovascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170712 |